Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Ixekizumab, ATC L04AC13 für die Zeit 01.07.2026 - 30.06.2028

Section 130a, paragraph 8 of the SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For the pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Ixekizumab, ATC L04AC13, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the licensing model for the aforementioned active substance comes into force for the first time on 01.07.2026 and expires on 30.06.2028. It automatically expires with the entry into force of the exclusive contract, regardless.